CROWN POINT, Ind. — OYE Therapeutics Inc. (“OYE” or the “Company”), a clinical-stage biopharmaceutical company developing intravenous caffeine-based therapies for acute care applications, today announced that the U.S. Food and Drug Administration (“FDA”) has merged two of the Company’s Investigational New Drug applications (“INDs”), creating a more streamlined regulatory framework for development across related programs.
The FDA action is expected to improve regulatory efficiency, reduce duplicative development activity, simplify operational execution and enhance capital efficiency as OYE advances its clinical-stage intravenous caffeine platform.
“This is a meaningful regulatory milestone for OYE Therapeutics,” said Brett Dines, CEO of OYE Therapeutics. “The FDA’s decision to merge two of our INDs supports a more unified development strategy across related programs and allows us to move forward with greater discipline, less duplication and stronger capital efficiency. We believe this action reinforces the platform potential of intravenous caffeine in acute care settings and enhances our ability to create value through efficient clinical and regulatory execution.”
By consolidating two previously separate IND pathways, OYE believes it can better align clinical development, regulatory submissions, program management and data strategy under a more efficient operating structure. The Company expects the merged IND framework to support sharper prioritization of development activities while preserving flexibility across multiple clinical applications.
OYE Therapeutics is developing differentiated intravenous caffeine product candidates intended to restore respiratory drive and neurologic function in acute care, perioperative and other clinically significant settings. The Company’s broader strategy is centered on leveraging the well-characterized pharmacology of caffeine, a targeted regulatory pathway, and a capital-efficient development model to pursue high-value indications with meaningful unmet need.
“OYE has always viewed its development strategy through both a scientific and capital allocation lens,” Dines said. “This FDA action improves both. It reduces friction in execution, supports more efficient deployment of resources, and strengthens our ability to advance the platform in a focused and value-driven manner.”
The Company intends to provide additional updates regarding development plans and clinical progress at appropriate milestones.
OYE operates from the Purdue Technology Center in the Purdue Research Park of Northwest Indiana .
About OYE Therapeutics
OYE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of intravenous caffeine-based therapies intended to improve outcomes in acute care and related medical settings. OYE’s platform is designed to rapidly stimulate respiratory drive and neurologic recovery in clinical situations in which restoring physiologic function quickly and reliably may offer meaningful therapeutic, operational and economic benefit.
Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including, but not limited to, statements regarding the anticipated benefits of the FDA merger of two INDs, regulatory efficiency, capital efficiency, operational execution, platform strategy, clinical development timing and future value creation. These forward-looking statements are based on current expectations, estimates, forecasts and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. OYE Therapeutics undertakes no obligation to update any forward-looking statements except as required by applicable law.
Media/Investor Contact: Mike Hicks, OYE Therapeutics Inc., Chief Operating Officer, 219-281-2369, mhicks@oyetherapeutics.com